Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Patients With Hepatorenal Syndrome
NCT06256432Phase 2Active, not recruiting
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ambrisentan in hepatorenal syndrome (HRS), sponsored by Noorik Biopharmaceuticals AG. Started Apr 2024; status: active, not recruiting.
02
Drugs
ambrisentan
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT06256432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256432.